|
Jun 12
|
Is the Options Market Predicting a Spike in Kura Oncology Stock?
|
|
Jun 12
|
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
|
|
May 23
|
Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025
|
|
May 22
|
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
|
|
Apr 29
|
Kura doses first subjects in trial of ziftomenib for advanced GIST
|
|
Apr 28
|
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
|
|
Apr 24
|
Kura Oncology to Report First Quarter 2025 Financial Results
|
|
Feb 19
|
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
|
|
Sep 30
|
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
|
|
Aug 8
|
Kura Oncology: Q2 Earnings Snapshot
|
|
Aug 8
|
Kura Oncology Reports Second Quarter 2024 Financial Results
|
|
Aug 8
|
Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
|
|
May 14
|
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
|
|
May 8
|
2 Incredible Growth Stocks to Buy Hand Over Fist
|
|
May 8
|
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
|
|
May 6
|
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Kura Oncology Inc (KURA) (Q1 2024) Earnings Call Transcript Highlights: Key Financial and ...
|
|
May 2
|
Kura Oncology Reports First Quarter 2024 Financial Results
|
|
Apr 25
|
Kura Oncology to Report First Quarter 2024 Financial Results
|
|
Apr 22
|
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
|